Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inamed To Carry On Quest For Silicone Implant Approval After Panel Rejection

This article was originally published in The Gray Sheet

Executive Summary

Inamed's 20% rupture rate for reconstruction breast implants would drop with the removal of the Style 153 double-lumen implants, according to members of FDA's General & Plastic Surgery Devices Panel

You may also be interested in...



Inamed Receives Silicone Breast Implant “Approvable” Letter From FDA

Inamed's silicone gel-filled breast implants inched closer to the market with the receipt of an FDA "approvable" letter, after the firm removed the controversial Style 153 implants from its PMA application

Inamed Receives Silicone Breast Implant “Approvable” Letter From FDA

Inamed's silicone gel-filled breast implants inched closer to the market with the receipt of an FDA "approvable" letter, after the firm removed the controversial Style 153 implants from its PMA application

Inamed’s Amended Silicone Breast Implant PMA Sheds Style 153 Model

Inamed expects its modified silicone breast implant premarket approval application to receive FDA approval by the end of the summer

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel